291 related articles for article (PubMed ID: 20113152)
1. Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma.
Sinakos E; Dedes I; Papalavrentios L; Drevelegas A; Akriviadis E
Scand J Gastroenterol; 2010 Apr; 45(4):511-2. PubMed ID: 20113152
[No Abstract] [Full Text] [Related]
2. Major achievements in hepatocellular carcinoma.
Bruix J; Llovet JM
Lancet; 2009 Feb; 373(9664):614-6. PubMed ID: 19231618
[No Abstract] [Full Text] [Related]
3. TACE with or without systemic therapy?
Dufour JF
J Hepatol; 2012 Jun; 56(6):1224-5. PubMed ID: 22402292
[No Abstract] [Full Text] [Related]
4. Clinical value of continuous administration of sorafenib in combination with modified transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.
Huang YH; Chen W; Li JP; Chen B; Yang JY
Chin Med J (Engl); 2013 Jan; 126(2):385-6. PubMed ID: 23324295
[No Abstract] [Full Text] [Related]
5. Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?
Sacco R; Antonucci M; Bargellini I; Marceglia S; Mismas V; Cabibbo G
Future Oncol; 2015; 11(17):2371-3. PubMed ID: 26270206
[No Abstract] [Full Text] [Related]
6. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma.
Park JW; Koh YH; Kim HB; Kim HY; An S; Choi JI; Woo SM; Nam BH
J Hepatol; 2012 Jun; 56(6):1336-42. PubMed ID: 22314421
[TBL] [Abstract][Full Text] [Related]
7. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794].
Hoffmann K; Glimm H; Radeleff B; Richter G; Heining C; Schenkel I; Zahlten-Hinguranage A; Schirrmacher P; Schmidt J; Büchler MW; Jaeger D; von Kalle C; Schemmer P
BMC Cancer; 2008 Nov; 8():349. PubMed ID: 19036146
[TBL] [Abstract][Full Text] [Related]
8. The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma.
Cabrera R; Pannu DS; Caridi J; Firpi RJ; Soldevila-Pico C; Morelli G; Clark V; Suman A; George TJ; Nelson DR
Aliment Pharmacol Ther; 2011 Jul; 34(2):205-13. PubMed ID: 21605146
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Geschwind JF; Chapiro J
Clin Adv Hematol Oncol; 2016 Aug; 14(8):585-7. PubMed ID: 27487101
[No Abstract] [Full Text] [Related]
10. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
Bai W; Wang YJ; Zhao Y; Qi XS; Yin ZX; He CY; Li RJ; Wu KC; Xia JL; Fan DM; Han GH
J Dig Dis; 2013 Apr; 14(4):181-90. PubMed ID: 23324079
[TBL] [Abstract][Full Text] [Related]
11. [Clinical observation of the treatment with combination of transcatheter arterial chemoembolization and sorafenib for hepatocellular carcinoma with lung metastasis].
Duan F; Wang MQ; Liu FY; Wang ZJ; Song P
Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):716-8. PubMed ID: 20021873
[TBL] [Abstract][Full Text] [Related]
12. [Clinical analysis of the treatment:transcatheter arterial chemoembolization combined with sorafenib in advanced hepatocellular carcinoma].
Li Y; Huang JW; Lu LG; Shao PJ; Hu BS; Huang GM; Wei ZG; Zhang L
Zhonghua Yi Xue Za Zhi; 2010 Aug; 90(31):2187-92. PubMed ID: 21029658
[TBL] [Abstract][Full Text] [Related]
13. [Clinical observation of transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma].
Xu LT; Chen Z; Lin JH; Zhou ZH; Chen H; Meng ZQ; Liu LM
Zhonghua Zhong Liu Za Zhi; 2010 Sep; 32(9):703-5. PubMed ID: 21122388
[TBL] [Abstract][Full Text] [Related]
14. Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results.
Cosgrove DP; Reyes DK; Pawlik TM; Feng AL; Kamel IR; Geschwind JF
Radiology; 2015 Nov; 277(2):594-603. PubMed ID: 26069923
[TBL] [Abstract][Full Text] [Related]
15. Selective internal radiation therapy of hepatocellular carcinoma: potential hepatopulmonary shunt reduction after sorafenib administration.
Theysohn JM; Schlaak JF; Müller S; Ertle J; Schlosser TW; Bockisch A; Lauenstein TC
J Vasc Interv Radiol; 2012 Jul; 23(7):949-52. PubMed ID: 22720895
[TBL] [Abstract][Full Text] [Related]
16. Management of hepatocellular carcinoma: an update.
Bruix J; Sherman M;
Hepatology; 2011 Mar; 53(3):1020-2. PubMed ID: 21374666
[No Abstract] [Full Text] [Related]
17. TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON.
Geschwind JF; Kudo M; Marrero JA; Venook AP; Chen XP; Bronowicki JP; Dagher L; Furuse J; Ladrón de Guevara L; Papandreou C; Sanyal AJ; Takayama T; Ye SL; Yoon SK; Nakajima K; Lehr R; Heldner S; Lencioni R
Radiology; 2016 May; 279(2):630-40. PubMed ID: 26744927
[TBL] [Abstract][Full Text] [Related]
18. [The treatment of hepatocellular carcinoma. New developments].
Kuiken SD; van Delden OM; Richel DJ; Jansen PL
Ned Tijdschr Geneeskd; 2009 Apr; 153(14):668-72. PubMed ID: 19425326
[No Abstract] [Full Text] [Related]
19. Early Sorafenib-related Biomarkers for Combination Treatment with Transarterial Chemoembolization and Sorafenib in Patients with Hepatocellular Carcinoma.
Zhong BY; Ni CF; Chen L; Zhu HD; Teng GJ
Radiology; 2017 Aug; 284(2):583-592. PubMed ID: 28263701
[TBL] [Abstract][Full Text] [Related]
20. Transarterial therapies for hepatocellular carcinoma (HCC): a long way towards standardization.
Tsochatzis EA; Meyer T; O'Beirne J; Burroughs AK
J Hepatol; 2013 Jan; 58(1):194. PubMed ID: 23046673
[No Abstract] [Full Text] [Related]
[Next] [New Search]